Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Microenvironment
Erschienen in: Cancer Microenvironment 1/2012

01.04.2012 | Original Paper

The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis

verfasst von: Eileen L. Heinrich, Tonya C. Walser, Kostyantyn Krysan, Elvira L. Liclican, Jeanette L. Grant, Nicole L. Rodriguez, Steven M. Dubinett

Erschienen in: Cancer Microenvironment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The inflammatory tumor microenvironment (TME) has many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of microRNAs (miRNAs) and an increase in a stem cell phenotype. Each of these has an impact on epithelial mesenchymal transition (EMT), particularly through the downregulation of E-cadherin. Here we review seminal work and recent findings linking the role of inflammation in the TME, EMT and lung cancer initiation, progression and metastasis. Finally, we discuss the potential of targeting aspects of inflammation and EMT in cancer prevention and treatment.
Literatur
1.
Barbieri SS, Weksler BB (2007) Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J 21:1831–1843PubMedCrossRef
2.
Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F et al (2004) Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 109:353–356PubMedCrossRef
3.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef
4.
Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248:171–183PubMedCrossRef
5.
6.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31–41PubMedCrossRef
7.
Apte RN, Krelin Y, Song X, Dotan S, Recih E et al (2006) Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42:751–759PubMedCrossRef
8.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081PubMedCrossRef
9.
De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429–447PubMedCrossRef
10.
Giatromanolaki A, Sivridis E, Koukourakis MI (2007) The Pathology of Tumor Stromatogenesis. Cancer Biol Ther 6
11.
Akashi T, Minami J, Ishige Y, Eishi Y, Takizawa T et al (2005) Basement membrane matrix modifies cytokine interactions between lung cancer cells and fibroblasts. Pathobiology 72:250–259PubMedCrossRef
12.
13.
Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715–725PubMedCrossRef
14.
Pokutta S, Weis WI (2007) Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol 23:237–261PubMedCrossRef
15.
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef
16.
Guarino M (2007) Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39:2153–2160PubMedCrossRef
17.
O’Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85:473–483PubMedCrossRef
18.
Kim V, Rogers TJ, Criner GJ (2008) New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:478–485PubMedCrossRef
19.
Samet JM (2000) Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 161:1–2PubMed
20.
Wipff PJ, Hinz B (2008) Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol 87:601–615PubMedCrossRef
21.
22.
Willis BC, Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293:L525–L534PubMedCrossRef
23.
24.
Adamson IY, Young L, Bowden DH (1988) Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol 130:377–383PubMed
25.
Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100:8621–8623PubMedCrossRef
26.
Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 100:8430–8435PubMedCrossRef
27.
Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ (2008) Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol 38:95–104PubMedCrossRef
28.
Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH et al (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175–183PubMedCrossRef
29.
Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745–756PubMedCrossRef
30.
Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125PubMedCrossRef
31.
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM et al (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416–428PubMedCrossRef
32.
Min C, Eddy SF, Sherr DH, Sonenshein GE (2008) NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104:733–744PubMedCrossRef
33.
Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT et al (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208–217PubMedCrossRef
34.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS et al (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073PubMed
35.
Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E et al (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65:6275–6281PubMedCrossRef
36.
Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K et al (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761–3764PubMed
37.
Krysan K, Dalwadi H, Sharma S, Pold M, Dubinett S (2004) Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64:6359–6362PubMedCrossRef
38.
Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc’h N et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483–1490PubMed
39.
Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K et al (2002) Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277:50828–50833PubMedCrossRef
40.
Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK et al (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66:5338–5345PubMedCrossRef
41.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925PubMedCrossRef
42.
Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. FASEB J 11:51–59PubMed
43.
Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848PubMedCrossRef
44.
Birchmeier C, Gherardi E (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8:404–410PubMedCrossRef
45.
Trusolino L, Bertotti A, Comoglio PM MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834–848
46.
Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT et al (1998) The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66:1915–1918PubMedCrossRef
47.
Siegfried JM, Luketich JD, Stabile LP, Christie N, Land SR (2004) Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest 125:116S–119SPubMedCrossRef
48.
Grotegut S, von Schweinitz D, Christofori G, Lehembre F (2006) Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 25:3534–3545PubMedCrossRef
49.
Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K et al (2001) Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20:8125–8135PubMedCrossRef
50.
Kominsky SL, Argani P, Korz D, Evron E, Raman V et al (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033PubMedCrossRef
51.
Toschi L, Janne PA (2008) Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 14:5941–5946PubMedCrossRef
52.
Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W et al (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686–8698PubMedCrossRef
53.
Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944–950PubMedCrossRef
54.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043PubMedCrossRef
55.
Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL et al (2008) Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 3:107–110PubMedCrossRef
56.
Apte RN, Voronov E (2002) Interleukin-1–a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12:277–290PubMedCrossRef
57.
Colasante A, Mascetra N, Brunetti M, Lattanzio G, Diodoro M et al (1997) Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. Am J Respir Crit Care Med 156:968–973PubMed
58.
Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA et al (2008) Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14:408–419PubMedCrossRef
59.
Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E et al (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67:1062–1071PubMedCrossRef
60.
Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P et al (1990) Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 50:4771–4775PubMed
61.
Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E et al (2008) Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 5:811–815PubMedCrossRef
62.
Lewis AM, Varghese S, Xu H, Alexander HR (2006) Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48PubMedCrossRef
63.
Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625–634PubMedCrossRef
64.
Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47PubMedCrossRef
65.
Nizet V, Johnson RS (2009) Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 9:609–617PubMedCrossRef
66.
Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC et al (2011) An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 186:1091–1096PubMedCrossRef
67.
Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ et al (2009) HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119:2160–2170PubMedCrossRef
68.
Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y et al (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117:3810–3820PubMed
69.
Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC et al (2006) Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66:3567–3575PubMedCrossRef
70.
Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H et al (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66:2725–2731PubMedCrossRef
71.
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295–305PubMedCrossRef
72.
Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH et al (2008) The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 27:1501–1510PubMedCrossRef
73.
Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS et al (2009) Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 64:1082–1089PubMedCrossRef
74.
Luo D, Wang J, Li J, Post M (2011) Mouse snail is a target gene for HIF. Mol Cancer Res 9:234–245PubMedCrossRef
75.
Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 105:6392–6397PubMedCrossRef
76.
Chen J, Imanaka N, Griffin JD (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 102:351–360PubMedCrossRef
77.
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361PubMedCrossRef
78.
Jiang YG, Luo Y, He DL, Li X, Zhang LL et al (2007) Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 14:1034–1039PubMedCrossRef
79.
Zhou G, Dada LA, Wu M, Kelly A, Trejo H et al (2009) Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol 297:L1120–L1130PubMedCrossRef
80.
Chen Y, Li D, Liu H, Xu H, Zheng H et al (2011) Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther 11:14–21PubMedCrossRef
81.
Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222–1226PubMedCrossRef
82.
Huang CH, Yang WH, Chang SY, Tai SK, Tzeng CH et al (2009) Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia 11:1371–1382PubMed
83.
Yoo YG, Christensen J, Huang LE (2011) HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 71:1244–1252PubMedCrossRef
84.
Albini A, Tosetti F, Benelli R, Noonan DM (2005) Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65:10637–10641PubMedCrossRef
85.
Pold M, Zhu LX, Sharma S, Burdick MD, Lin Y et al (2004) Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 64:1853–1860PubMedCrossRef
86.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRef
87.
Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336–3340PubMedCrossRef
88.
Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ et al (2001) Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276:20809–20812PubMedCrossRef
89.
Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S (2005) Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129:1375–1383PubMedCrossRef
90.
Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC et al (2009) Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res 15:6820–6829PubMedCrossRef
91.
Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY et al (2000) Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 162:1957–1963PubMed
92.
Strieter RM (2008) Out of the shadows: CXC chemokines in promoting aberrant lung cancer angiogenesis. Cancer Prev Res (Phila) 1:305–307CrossRef
93.
Sun H, Chung WC, Ryu SH, Ju Z, Tran HT et al (2008) Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila) 1:316–328CrossRef
94.
Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD et al (2006) High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66:4198–4207PubMedCrossRef
95.
Framson PE, Sage EH (2004) SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92:679–690PubMedCrossRef
96.
Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P et al (2006) SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66:7516–7523PubMedCrossRef
97.
Seno T, Harada H, Kohno S, Teraoka M, Inoue A et al (2009) Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34:707–715PubMedCrossRef
98.
Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312PubMedCrossRef
99.
De Wever O, Demetter P, Mareel M, Bracke M (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123:2229–2238PubMedCrossRef
100.
Sato N, Maehara N, Goggins M (2004) Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64:6950–6956PubMedCrossRef
101.
Rowe RG, Weiss SJ (2008) Breaching the basement membrane: who, when and how? Trends Cell Biol 18:560–574PubMedCrossRef
102.
Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273PubMedCrossRef
103.
Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ (2005) Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 280:11740–11748PubMedCrossRef
104.
Zhou BP, Deng J, Xia W, Xu J, Li YM et al (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6:931–940PubMedCrossRef
105.
Ota I, Li XY, Hu Y, Weiss SJ (2009) Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A 106:20318–20323PubMedCrossRef
106.
Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P et al (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 167:769–781PubMedCrossRef
107.
Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF et al (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26:7859–7871PubMedCrossRef
108.
Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19:816–827PubMedCrossRef
109.
Sasaki T, Miosge N, Timpl R (1999) Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biol 18:499–508PubMedCrossRef
110.
Tremble PM, Lane TF, Sage EH, Werb Z (1993) SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 121:1433–1444PubMedCrossRef
111.
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L et al (1997) Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3:171–176PubMedCrossRef
112.
Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM et al (1998) SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58:5529–5536PubMed
113.
Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC et al (2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63:5376–5380PubMed
114.
Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP et al (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25:319–325PubMedCrossRef
115.
Nomura S, Hashmi S, McVey JH, Ham J, Parker M et al (1989) Evidence for positive and negative regulatory elements in the 5′-flanking sequence of the mouse sparc (osteonectin) gene. J Biol Chem 264:12201–12207PubMed
116.
Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B et al (2008) Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68:9050–9059PubMedCrossRef
117.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811PubMedCrossRef
118.
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531PubMedCrossRef
119.
Gregory PA, Bracken CP, Bert AG, Goodall GJ (2008) MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7:3112–3118PubMedCrossRef
120.
Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25:6188–6196PubMedCrossRef
121.
122.
Tanzer A, Stadler PF (2004) Molecular evolution of a microRNA cluster. J Mol Biol 339:327–335PubMedCrossRef
123.
Oglesby IK, McElvaney NG, Greene CM (2010) MicroRNAs in inflammatory lung disease–master regulators or target practice? Respir Res 11:148PubMedCrossRef
124.
O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839–843PubMedCrossRef
125.
Mu P, Han YC, Betel D, Yao E, Squatrito M et al (2009) Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23:2806–2811PubMedCrossRef
126.
Houbaviy HB, Murray MF, Sharp PA (2003) Embryonic stem cell-specific MicroRNAs. Dev Cell 5:351–358PubMedCrossRef
127.
Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL (2007) Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 310:442–453PubMedCrossRef
128.
Kim JW, Mori S, Nevins JR (2010) Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 70:4820–4828PubMedCrossRef
129.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:247–256PubMed
130.
Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D et al (2009) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29:1394–1404PubMedCrossRef
131.
Vetter G, Saumet A, Moes M, Vallar L, Le Bechec A et al (2010) miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 29:4436–4448PubMedCrossRef
132.
Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688PubMedCrossRef
133.
Cottonham CL, Kaneko S, Xu L (2010) miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285:35293–35302PubMedCrossRef
134.
Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, et al. (2011) MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene
135.
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659PubMedCrossRef
136.
Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML (1999) Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 19:3439–3445PubMed
137.
Yuan A, Farber EL, Rapoport AL, Tejada D, Deniskin R et al (2009) Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 4:e4722PubMedCrossRef
138.
Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C (2010) Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 123:1603–1611PubMedCrossRef
139.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518PubMedCrossRef
140.
Brase JC, Wuttig D, Kuner R, Sultmann H (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306PubMedCrossRef
141.
Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II et al (2011) Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med 32:32–43PubMedCrossRef
142.
Sullivan JP, Minna JD, Shay JW (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29:61–72PubMedCrossRef
143.
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751PubMedCrossRef
144.
Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715PubMedCrossRef
145.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820–13825PubMedCrossRef
146.
Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ et al (2009) A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev 23:1737–1742PubMedCrossRef
147.
Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY et al (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12:982–992PubMedCrossRef
148.
Giannoni E, Bianchini F, Calorini L, Chiarugi P (2011) Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal.
149.
Louie E, Nik S, Chen JS, Schmidt M, Song B, et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 12: R94
150.
Kurrey NK KA, Bapat SA (2005) Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 97:155–165PubMedCrossRef
151.
Pinho AV, Rooman I, Real FX (2011) p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 10:1312–1321PubMedCrossRef
152.
Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y et al (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13:317–323PubMedCrossRef
153.
May R, Sureban SM, Hoang N, Riehl TE, Lightfoot SA et al (2009) Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells 27:2571–2579PubMedCrossRef
154.
Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G et al (2009) Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 137:649–659, 659 e641-642PubMedCrossRef
155.
Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71: 2328–2338
156.
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, et al. (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
157.
Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G et al (2011) The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 30:770–782PubMedCrossRef
158.
Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL et al (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71:3087–3097PubMedCrossRef
159.
Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H (2009) Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 66:275–281PubMedCrossRef
160.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R et al (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11:R46PubMedCrossRef
161.
Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C et al (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70:9937–9948PubMedCrossRef
162.
Soberman RJ, Christmas P (2006) Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation. Am J Physiol Lung Cell Mol Physiol 291:L142–L143PubMedCrossRef
163.
Tomaki M, Sugiura H, Koarai A, Komaki Y, Akita T et al (2007) Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung. Pulm Pharmacol Ther 20:596–605PubMedCrossRef
Metadaten
Titel
The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis
verfasst von
Eileen L. Heinrich
Tonya C. Walser
Kostyantyn Krysan
Elvira L. Liclican
Jeanette L. Grant
Nicole L. Rodriguez
Steven M. Dubinett
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1/2012
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-011-0089-0

Weitere Artikel der Ausgabe 1/2012

Cancer Microenvironment 1/2012 Zur Ausgabe

Original Paper

Transforming Growth Factor-β1 (TGF-β1) Driven Epithelial to Mesenchymal Transition (EMT) is Accentuated by Tumour Necrosis Factor α (TNFα) via Crosstalk Between the SMAD and NF-κB Pathways

Preface

Soiling the Seed: Microenvironment and Epithelial Mesenchymal Plasticity

Original Paper

Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition

Original Paper

Regulation of Epithelial-Mesenchymal Transition by Transmission of Mechanical Stress through Epithelial Tissues

Original Paper

Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases

OriginalPaper

The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise